Drug Profile
Research programme: transduced autologous restorative gene therapy - Avalo Therapeutics
Alternative Names: Hemodure™; TARGTCNSLatest Information Update: 30 Aug 2021
Price :
$50
*
At a glance
- Originator Medgenics
- Developer Avalo Therapeutics; Harvard University; Medgenics
- Class Gene therapies; Interferons; Proteins
- Mechanism of Action Blood coagulation factor replacements; Factor X stimulants; Gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported CNS disorders
- Discontinued Haemophilia A
Most Recent Events
- 26 Aug 2021 Cerecor is now called Avalo Therapeutics
- 03 Feb 2020 Aevi Genomic Medicine has been acquired and merged into Cerecor
- 28 May 2019 No recent reports of development identified for preclinical development in CNS-disorders in USA